Our DxPP™ Accelerates Every Phase of the Oncology Drug Development Process
De-risk Phase I trials with human-relevant tumor models
-
Strengthen regulatory submissions, supporting Investigational New Drug [LS1] (IND) submissions, FDA Breakthrough Therapy Designation, Orphan Drug Designation and PREA compliance as well as NIH Precision Medicine Initiatives
-
Discover novel drug combinations and pursue label expansion opportunities across new indications
-
Uncover functional biomarkers tied to actual cancer behavior, no longer relying on predictive models
How It Works
We Work With Your Doctor Wherever You Are and Bring Clarity in 3 Simple Steps:
1. Collect a fresh biopsy sample for target cancers from solid or hematologic cancers
2. Test compounds and combinations ex vivo
3. DxPP delivers prioritized insights in target populations in an average of 10 days
Proven, Peer-Reviewed, and Ready to Scale
Unlike genomics-only platforms or simulated AI models, First Ascent Biomedical data are grounded in real cancer cell response. Validated, published, and actionable in near real time, we deliver on the promise to transform the clinical trial process by validating drug response in controlled settings against a selected patient population.
- Faster, More Effective Development — By accurately predicting drug response in a near-human microenvironment, reduces early-stage timelines and costs, generating the data to accelerate FDA submissions and market entry.
- Reduced Clinical Trial Risk — Improve patient targeting and trial design.
- Safer Human Trials — De-risks Phase I studies by pre-qualifying compounds in human-relevant models, reducing reliance on In Silico and animal testing.
- Unlock Portfolio Value — Identifies new combinations and indications to extend the value of existing assets, including those nearing loss of exclusivity.
- Hard Science, Real World Validation — Backed by top journals and trusted by global pharmaceutical companies.
Let’s Accelerate Your Next Oncology Breakthrough
Join the Innovators Transforming Oncology
With DxPP, pharma teams gain a new lens for discovery, validation, and faster regulatory success—grounded in real-world patient biology.
Are you a non-profit or advocacy group interested in supporting patient access to First Ascent’s mission?
You play a vital role in every patient’s cancer journey, providing support, advancing research, and driving hope. By partnering with First Ascent Biomedical you can help guide treatment, directly impacting cancer patients today!